Art. -Nr.: HY-W013857

Lavendustin C

Kundenbewertung

Based on 1 Customer Validation

Lavendustin C is a potent Ca²⁺ calmodulin-dependent kinase II (CaMK II) inhibitor with an IC₅₀ of 0.2 μM. Lavendustin C inhibits EGFR-associated tyrosine kinase (IC₅₀=0.012 μM) and pp60^c-src(+) kinase (IC₅₀=0.5 μM) .

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.17%
CAS. Nr.: 125697-93-0
Formel: C₁₄H₁₃NO₅
Molecular Weight:275.26

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Lavendustin C Chemical Structure

CAS. Nr.: 125697-93-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]^[2]

CaMK II

0.2 μM (IC₅₀)

EGFR

0.012 μM (IC₅₀)

Alle CaMK Isoform-spezifische Produkte anzeigen :

Alle EGFR Isoform-spezifische Produkte anzeigen :

Alle Src Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	IC₅₀	4 μM Compound: 2	Displacement of [gamma-32P]-ATP from Epidermal growth factor receptor in A431 cell-free extracts Displacement of [gamma-32P]-ATP from Epidermal growth factor receptor in A431 cell-free extracts	10.1016/S0960-894X(97)00014-0
ER22	IC₅₀	0.15 μM Compound: II12	Inhibition of EGFR(epidermal growth factor receptor) autophosphorylation in ER22 cell membranes Inhibition of EGFR(epidermal growth factor receptor) autophosphorylation in ER22 cell membranes	[PMID: 8145236]
ER22	IC₅₀	92 μM Compound: II12	Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells Inhibition of EGF-stimulated DNA synthesis in ER22 cells, by measuring [3H]Me-dT incorporation into ER 22 cells	[PMID: 8145236]
HaCaT	IC₅₀	>100 μM Compound: 3	Cytotoxicity against human HaCaT cells Cytotoxicity against human HaCaT cells	[PMID: 20570145]
HaCaT	IC₅₀	>=100 μM Compound: 2	Inhibitory activity of HaCaT keratinocyte cell line Inhibitory activity of HaCaT keratinocyte cell line	[PMID: 7990108]
HEK293	IC₅₀	1.34 μM Compound: 8c	Inhibition of NOX4 expressed in HEK293 FS cells assessed as H2O2 production by H2O2/Tyr/LPO assay Inhibition of NOX4 expressed in HEK293 FS cells assessed as H2O2 production by H2O2/Tyr/LPO assay	[PMID: 20731357]

In Vitro

Lavendustin C (Compound 5) shows potent inhibitory activity, and it may be the core structure responsible for inhibition of tyrosine kinase^[1].
Lavendustin C (10-150 μM) inhibits tyrosine kinase-associated neutrophil degranulation and superoxide generation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 125697-93-0
Appearance Solid
Molecular Weight 275.26
Formel C₁₄H₁₃NO₅
Color Off-white to light yellow
SMILES

O=C(O)C1=CC(NCC2=CC(O)=CC=C2O)=CC=C1O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (363.29 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.6329 mL

18.1646 mL

36.3293 mL

5 mM

0.7266 mL

3.6329 mL

7.2659 mL

10 mM

0.3633 mL

1.8165 mL

3.6329 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.08 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (9.08 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.08 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. T Onoda, et al.Isolation of a Novel Tyrosine Kinase Inhibitor, Lavendustin A, From Streptomyces Griseolavendus. J Nat Prod. Nov-Dec 1989;52(6):1252-7. [Content Brief]

[2]. T J O'Dell, et al.Long-term Potentiation in the Hippocampus Is Blocked by Tyrosine Kinase Inhibitors. Nature. 1991 Oct 10;353(6344):558-60. [Content Brief]

[3]. H M Burt, et al. Inhibition of Crystal-Induced Neutrophil Activation by a Protein Tyrosine Kinase Inhibitor. J Leukoc Biol. 1994 Jan;55(1):112-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.6329 mL	18.1646 mL	36.3293 mL	90.8232 mL
	5 mM	0.7266 mL	3.6329 mL	7.2659 mL	18.1646 mL
	10 mM	0.3633 mL	1.8165 mL	3.6329 mL	9.0823 mL
	15 mM	0.2422 mL	1.2110 mL	2.4220 mL	6.0549 mL
	20 mM	0.1816 mL	0.9082 mL	1.8165 mL	4.5412 mL
	25 mM	0.1453 mL	0.7266 mL	1.4532 mL	3.6329 mL
	30 mM	0.1211 mL	0.6055 mL	1.2110 mL	3.0274 mL
	40 mM	0.0908 mL	0.4541 mL	0.9082 mL	2.2706 mL
	50 mM	0.0727 mL	0.3633 mL	0.7266 mL	1.8165 mL
	60 mM	0.0605 mL	0.3027 mL	0.6055 mL	1.5137 mL
	80 mM	0.0454 mL	0.2271 mL	0.4541 mL	1.1353 mL
	100 mM	0.0363 mL	0.1816 mL	0.3633 mL	0.9082 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Lavendustin C

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Neuronal Signaling Compound Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Anti-Hepatitis C Virus Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cytokine Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Lipid Metabolite Compound Library

Alle CaMK Isoform-spezifische Produkte anzeigen

Alle EGFR Isoform-spezifische Produkte anzeigen

Alle Src Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Lavendustin C Related Classifications

HY-W013857 Related Classifications